Amgen (NASDAQ:AMGN) Stock Acquired by Rep. David Taylor

Posted by George Bondi on Oct 4th, 2026

Representative David Taylor (Republican-Ohio) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on October 1st, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on September 22nd. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Marathon Petroleum (NYSE:MPC) on 9/22/2026.
Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/22/2026.
Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 9/8/2026.
Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 9/8/2026.
Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 8/26/2026.
Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 8/26/2026.
Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 8/26/2026.

Amgen Stock Down 1.0%

NASDAQ AMGN opened at $403.04 on Friday. The stock’s 50 day simple moving average is $410.72 and its 200 day simple moving average is $370.33. Amgen Inc. has a one year low of $288.00 and a one year high of $447.03. The firm has a market cap of $217.90 billion, a PE ratio of 25.05, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.5%. Amgen’s dividend payout ratio is 62.65%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on AMGN shares. Morgan Stanley reiterated an “overweight” rating and set a $362.00 price target on shares of Amgen in a research report on Wednesday, August 19th. Truist Financial raised their price target on shares of Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Scotiabank upped their price objective on Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a report on Monday, September 28th. Barclays upped their price target on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Amgen in a research report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $385.25.

Check Out Our Latest Stock Analysis on Amgen

Insider Activity

In other news, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 in the last quarter. 0.85% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Amgen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMGN. Wellington Altus USA Inc. grew its holdings in shares of Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after buying an additional 34 shares during the period. Tower View Wealth Management LLC grew its stake in Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares during the period. Security National Bank of Sioux City Iowa IA acquired a new position in Amgen in the second quarter valued at about $36,000. Evergreen Advisors LLC bought a new stake in shares of Amgen in the first quarter worth about $37,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in shares of Amgen in the fourth quarter worth about $44,000. Institutional investors own 76.50% of the company’s stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

(Get Free Report)

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.